Korean J Urol Oncol.  2016 Apr;14(1):39-42. 10.0000/kjuo.2016.14.1.39.

Routine Use of Single Instillation of Epirubicin after Transurethral Resection of Bladder Tumor - Should It Be Done in Korean Patients?

• Shin YS
• Kim MK
• Jeong YB
• Kim HJ

• KMID: 2411178
• DOI: http://doi.org/10.0000/kjuo.2016.14.1.39

Abstract

To study the impact of single instillation of epirubicin (SIE) on the cancer recurrence of non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT) in Korean patients. The major inclusion criteria were NMIBC patients. The major exclusion criteria were muscle invasive bladder cancer, metastatic bladder cancer, combined urinary upper tract tumor, and carcinoma in situ. SIE group received 50 mg epirubicin within 6 hours after TURBT. Non-SIE group did not receive epirubicin. This study enrolled a total of 214 patients diagnosed as having NMIBC during the period from October 2003 through January 2010 at the single institutions. Follow-up of the patients was conducted through January 2012. The median age of patients was 63.4 years. Of 112 evaluable patients in the SIE group, cancer recurrence rate was 33.9% and in non-SIE group, cancer recurrence rate was 62.7% (p<0.001). The recurrence-free survival duration was longer in Group SIE compared with Group non-SIE (p<0.001). Multivariate analysis revealed that SIE was significantly associated with cancer recurrence (HR 0.213, p<0.001). We confirmed the impact of SIE on the cancer recurrence in the Korean patients who underwent TURBT for NMIBC. Single instillation of chemo-agent after TUR-B might be recommended in Korean patients for reduce bladder cancer recurrence and provide longer recurrence-free survival duration.

Keyword

Bladder cancer; Epirubicin; Recurrence

MeSH Terms

Carcinoma in Situ
Epirubicin*
Follow-Up Studies
Humans
Multivariate Analysis
Recurrence
Urinary Bladder Neoplasms*
Urinary Bladder*
Epirubicin